UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility BIA-ALCL in anyone implants and new symptoms crucial to early diagnosis. The tumour begins on inner aspect peri-implant capsule causing effusion, or less commonly a tissue mass form within capsule, which may spread locally more distant sites body. Diagnosis usually made by cytological, immunohistochemical immunophenotypic evaluation fluid: pleomorphic lymphocytes are characteristically kinase (ALK) negative strongly positive for CD30. indolent most patients but can progress rapidly. Surgical removal implant intact surrounding (total en-bloc capsulectomy) curative. Late diagnosis require radical surgery systemic therapies although these successful, poor outcomes deaths have been reported. By adopting structured approach, as suggested guidelines, successful treatment will minimize need treatments, reduce morbidity risk outcomes. These guidelines provide evidence-based systematic framework assessment suspected proven aimed at all clinicians involved care people